Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)
June 19 2015 - 12:32PM
Edgar (US Regulatory)
Filed by Teva Pharmaceutical Industries Ltd.
(Commission File No. 001-16174) pursuant to
Rule 425 under the Securities Act of 1933
and deemed filed pursuant to Rule 14a-12 under
the Securities Exchange Act of 1934
Subject Company: Mylan N.V.
Commission File No.: 333-199861
TEVA COMPLETES THE PURCHASE OF 4.61 PERCENT INTEREST IN MYLAN N.V.
JERUSALEM June 19, 2015 Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that it has completed the purchase
of 4.61 percent of all outstanding shares of Mylan N.V. (NASDAQ: MYL), which will enable Teva to commence proceedings before the Dutch Enterprise Chamber, should it become necessary.
Teva has advised Stichting Preferred Shares Mylan that if the Mylan Extraordinary General Meeting (EGM) on the Perrigo transaction is held no
later than August 31, 2015, Teva will limit its aggregate shareholding in Mylan prior to the EGM to less than 5 percent of the outstanding shares of Mylan.
Barclays and Greenhill & Co. are serving as financial advisors to Teva. Sullivan & Cromwell LLP is serving as legal counsel to Teva, with De
Brauw Blackstone Westbroek N.V. acting as legal advisor in the Netherlands.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare
solutions to millions of patients every day. Headquartered in Israel, Teva is the worlds largest generic medicines producer, leveraging its portfolio of more than 1,000 molecules to produce a wide range of generic products in nearly every
therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and
specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Tevas net revenues in 2014 amounted
to $20.3 billion. For more information, visit www.tevapharm.com.
Safe Harbor Statement
This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on
managements current beliefs and expectations and involve a number of assumptions, known and unknown risks and uncertainties that change over time and could cause future results, performance or achievements to differ materially from the
results, performance or achievements expressed or implied by such forward-looking statements. These assumptions, known and unknown risks and uncertainties include, but are not limited to, those discussed in our Annual Report on Form 20-F for the
year ended December 31, 2014 and in our other filings with the U.S. Securities and Exchange Commission (the SEC), and those relating to Mylans business, as detailed from time to time in Mylans filings with the SEC, which
factors are incorporated herein by reference. Forward-looking statements are generally identified by the words expects, anticipates, believes, intends, estimates, will,
would, could, should, may, plans and similar expressions. All statements, other than statements of historical fact, are statements that could be deemed to be forward-looking statements,
including statements about the proposed acquisition of Mylan, the financing of the proposed transaction, the expected future performance (including expected results of operations and financial guidance), and the combined companys future
financial condition, operating results, strategy and plans. Important factors that could cause actual results, performance or achievements to differ materially from the forward-looking statements we make in this communication include, but are not
limited to: the ultimate outcome of
any possible transaction between Teva and Mylan, including the possibility that no transaction between Teva and Mylan will be effected or that a transaction will be pursued on different terms and
conditions; the effects of the business combination of Teva and Mylan, including the combined companys future financial condition, operating results, strategy and plans; uncertainties as to the timing of the transaction; the possibility that
the expected benefits of the transaction and the integration of our operations with Mylans operations (including any expected synergies) will not be fully realized by us or may take longer to realize than expected; adverse effects on the
market price of Tevas or Mylans shares, including negative effects of this communication or the consummation of the possible transaction; the ability to obtain regulatory approvals on the terms proposed or expected and satisfy other
conditions to the offer, including any necessary stockholder approval, in each case, on a timely basis; our and Mylans ability to comply with all covenants in our or its current or future indentures and credit facilities, any violation of
which, if not cured in a timely manner, could trigger a default of other obligations under cross default provisions; our and Mylans exposure to currency fluctuations and restrictions as well as credit risks; the effects of reforms in
healthcare regulation and pharmaceutical pricing and reimbursement; uncertainties surrounding the legislative and regulatory pathways for the registration and approval of biotechnology-based medicines; the impact of competition from other market
participants; adverse effects of political or economic instability, corruption, major hostilities or acts of terrorism on our or Mylans significant worldwide operations; other risks, uncertainties and other factors detailed in our Annual
Report on Form 20-F for the year ended December 31, 2014 and in our other filings with the SEC; and the risks and uncertainties and other factors detailed in Mylans reports and documents filed with the SEC. All forward-looking statements
attributable to us or any person acting on our behalf are expressly qualified in their entirety by this cautionary statement. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Forward-looking statements
speak only as of the date on which they are made and we assume no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
ADDITIONAL INFORMATION
This communication is for
informational purposes only and does not constitute an offer to buy or solicitation of an offer to sell any securities. This communication relates to a proposal which Teva has made for a business combination transaction with Mylan. In furtherance of
this proposal and subject to future developments, Teva and Mylan may file one or more proxy statements, registration statements or other documents with the SEC. This communication is not a substitute for any proxy statement, registration statement,
prospectus or other document Teva and/or Mylan have filed or may file with the SEC in connection with the proposed transaction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of
the U.S. Securities Act of 1933, as amended. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT(s), REGISTRATION STATEMENT, PROSPECTUS AND OTHER DOCUMENTS THAT MAY BE FILED WITH THE SEC CAREFULLY IN THEIR ENTIRETY IF AND WHEN THEY
BECOME AVAILABLE AS THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Any definitive proxy statement(s) (if and when available) will be mailed to stockholders. Investors and security holders may obtain free copies of this
communication, any proxy statement, registration statement, prospectus and other documents (in each case, if and when available) filed with the SEC by Teva through the web site maintained by the SEC at http://www.sec.gov. Information about certain
individuals who may be deemed to be participants in a solicitation of shareholders of Mylan in respect of Mylans proposal for a business combination with Perrigo Company plc and a description of their direct or indirect interests by security
holdings or otherwise can be found in the report on Form 6-K furnished by Teva with the SEC on June 8, 2015.
Contacts
|
|
|
Investors |
|
|
United States |
|
Israel |
Kevin C. Mannix
215-591-8912 |
|
Tomer Amitai 972 (3) 926-7656 |
Ran Meir
215-591-3033 |
|
|
|
|
|
D.F. King & Co., Inc. Jordan Kovler / Tom
Germinario 212- 269-5550 |
|
|
|
|
Media |
|
|
Teva United States |
|
Teva Israel |
Denise Bradley 215-591-8974 |
|
Iris Beck Codner 972 (3) 926-7687 |
|
|
United States |
|
The Netherlands |
Joele Frank, Wilkinson Brimmer Katcher Joele
Frank / Tim Lynch / Meaghan Repko 212-355-4449 |
|
Citigate First Financial Uneke Dekkers / Petra
Jager / Suzanne Bakker + 31 20 575 40 10 |
Mylan NV (NASDAQ:MYL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Mylan NV (NASDAQ:MYL)
Historical Stock Chart
From Sep 2023 to Sep 2024